Recent News Releases
Latest CSL News
$2.5 Million Funding Available to Australian Biomedical Researchers
Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies
New Patent Box policy will benefit domestic commercialisation of medical research
Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.
uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.
Four Australian Research Programs to be Fast-Tracked in Partnership with CSL
Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19
CSL is pleased to confirm that the final stages of manufacturing of the AstraZeneca COVID-19 vaccine for Australia are planned to commence next week, with first doses on track for release towards the end of March, subject to approval by the Therapeutic Goods Administration (TGA).
24 healthy volunteers to be recruited for study of plasma-derived COVID-19 Immunoglobulin
CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne.
Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year
CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office in Melbourne and will join CSL’s Global Leadership Group.
Senior Manager, Communications
Phone: +61 429 609 762